Bieżący numer
Archiwum
Online first
O czasopiśmie
Redakcja
Rada Naukowa
Wydawca
Standardy etyczne i procedury
Bazy indeksacyjne
Recenzenci
Recenzenci Honorowi
Prenumerata
Kontakt
Najczęściej czytane artykuły
Dla autorów
Opłata za przetwarzanie artykułu (APC)
Książki i Konferencje
Książki
Konferencje
SARS CoV-2/COVID-19
PRZEGLĄD LITERATURY NA PODSTAWIE PRZYPADKÓW
Chronic intestinal pseudo-obstruction in the course of systemic sclerosis successfully treated with intravenous immunoglobulins and rituximab
1
The Student Scientific Society of Poznan University of Medical Sciences, Poland
2
Student’s Research Group of Rheumatology, Systemic Connective Tissue Diseases, and Immunotherapy of Rheumatic Diseases, Poznan University of Medical Sciences, Poland
3
Department of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Poland
4
Department of Rheumatology, Systemic Connective Tissue Diseases, and Immunotherapy of Rheumatic Diseases at Józef Struś Hospital in Poznan, Poland
Data nadesłania: 14-10-2024
Data ostatniej rewizji: 02-12-2024
Data akceptacji: 02-12-2024
Data publikacji online: 28-05-2025
Autor do korespondencji
Julia Kołodziejczyk
Student’s Research Group of Rheumatology, Systemic Connective Tissue Diseases and Immunotherapy of Rheumatic Diseases, Poznan University of Medical Sciences, 10 Fredry St., 61-701 Poznan, Poland
Student’s Research Group of Rheumatology, Systemic Connective Tissue Diseases and Immunotherapy of Rheumatic Diseases, Poznan University of Medical Sciences, 10 Fredry St., 61-701 Poznan, Poland
SŁOWA KLUCZOWE
DZIEDZINY
Twardzina układowa, myositis i powiązane zespoły - etiologia, patogeneza, obraz kliniczny i leczenieOcena aktywności choroby i jakości życia w chorobach reumatycznychNowe terapie w chorobach reumatycznychDiagnostyka laboratoryjna I obrazowa chorób reumatycznych
STRESZCZENIE
Chronic intestinal pseudo-obstruction (CIPO) is an infrequent and menacing complication of systemic sclerosis (Ssc). While researchers report positive impact of rituximab (RTX) on CIPO in paraneoplastic syndrome, no case reports exist for SSc-associated CIPO. The aim of this case-based review is to analyses current literature in context of particular CIPO case description.
This analysis was based on PubMed/MEDLINE database and was conducted using the selected key terms. Finally 40 studies/case reports and one case description from authors clinical experience were included into comparison and discussion.
As conclusion description of successfuly treatment with RTX and intravenous immunoglobulins can confirm the suggestions from other studies that B-cells participate in the pathogenesis of SSc, making RTX a potentially effective therapeutic option also in coexisting CIPO.
REFERENCJE (39)
1.
Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet 2023; 401: 304–318, DOI: 0.1016/S0140-6736(22)01692-0.
2.
Nassar M, Ghernautan V, Nso N, et al. Gastrointestinal involvement in systemic sclerosis: an updated review. Medicine (Baltimore) 2022; 101: e31780, DOI: 10.1097/MD.0000000000031780.
3.
Alastal Y, Hammad TA, Renno A, et al. Gastrointestinal manifestations associated with systemic sclerosis: results from the nationwide inpatient sample. Ann Gastroenterol 2017; 30: 498–503, DOI: 10.20524/aog.2017.0171.
4.
Marie I, Ducrotté P, Denis P, et al. Outcome of small-bowel motor impairment in systemic sclerosis – a prospective manometric 5-yr follow-up. Rheumatology (Oxford) 2007; 46: 150–153, DOI: 10.1093/rheumatology/kel203.
5.
Valenzuela A, Li S, Becker L, et al. Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. Rheumatology (Oxford) 2016; 55: 654–658, DOI: 10.1093/rheumatology/kev393.
6.
Pamarthy R, Berumen A, Breen-Lyles M, et al. Comparing Clinical, Imaging, and Physiological Correlates of Intestinal Pseudo-Obstruction: Systemic Sclerosis vs Amyloidosis and Paraneoplastic Syndrome. Clin Transl Gastroenterol 2020; 11: e00206, DOI: 10.14309/ctg.0000000000000206.
7.
Vigone B, Beretta L. Abatacept to treat chronic intestinal pseudo- obstruction in five systemic sclerosis patients with a description of the index case. J Scleroderma Relat Disord 2019; 4: NP5–NP9, DOI: 10.1177/2397198318766819.
8.
Zenzeri L, Tambucci R, Quitadamo P, Giorgio V, et al. Update on chronic intestinal pseudo-obstruction. Curr Opin Gastroenterol 2020; 36: 230–237, DOI: 10.1097/MOG.0000000000000630.
9.
Zhang H, Cong JC, Chen CS. Ileum perforation due to delayed operation in obturator hernia: a case report and review of literatures. World J Gastroenterol 2010; 16: 126–130, DOI: 10.3748/wjg.v16.i1.126.
10.
Matsuda KM, Yoshizaki A, Kuzumi A, et al. Rapid improvement of systemic sclerosis-associated intestinal pseudo- obstruction with intravenous immunoglobulin administration. Rheumatology (Oxford) 2023; 62: 3139–3145, DOI: 10.1093/rheumatology/kead093.
11.
Folwaczny C, Läritz M, Meurer M, et al. Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma. Z Gastroenterol 1997; 35: 905–912.
12.
Vigone B, Caronni M, Severino A, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther 2017; 19: 145, DOI: 10.1186/s13075-017-1340-y.
13.
Wang DX, Shu XM, Tian XL, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol 2012; 31: 801–806, DOI: 10.1007/s10067-012-1940-5.
14.
Sanges S, Rivière S, Mekinian A, et al. Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev 2017; 16: 377–384, DOI: 10.1016/j.autrev.2017.02.008.
15.
Briani C, Visentin A. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies. Neurotherapeutics 2022; 19: 874–884, DOI: 10.1007/s13311-022-01222-x.
16.
Badari A, Farolino D, Nasser E, et al. A novel approach to paraneoplastic intestinal pseudo-obstruction. Support Care Cancer 2012; 20: 425–428, DOI: 10.1007/s00520-011-1305-7.
17.
Drukker CAM, Heij HA, Wijnaendts LCD, et al. Paraneoplastic gastro-intestinal anti-Hu syndrome in neuroblastoma. Pediatr Blood Cancer 2009; 52: 396–398, DOI: 10.1002/pbc.21807.
18.
Coret F, Bosca I, Fratalia L, et al. Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction. J Neurooncol 2009; 93: 421–423, DOI: 10.1007/s11060-008-9787-y.
19.
Shams’ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253: 16–20, DOI: 10.1007/s00415-005-0882-0.
20.
Volkmann ER, McMahan Z. Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment, and treatment. Curr Opin Rheumatol 2022; 34: 328–336, DOI: 10.1097/BOR. 0000000000000899.
21.
Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437–2444, DOI: 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U.
22.
Jaovisidha K, Csuka ME, Almagro UA, Soergel KH. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum 2005; 34: 689–702, DOI: 10.1016/j.semarthrit.2004.08.009.
23.
Mecoli C, Purohit S, Sandorfi N, Derk CT. Mortality, Recurrence, and Hospital Course of Patients with Systemic Sclerosis- related Acute Intestinal Pseudo-obstruction. J Rheumatol 2014; 41: 2049–2054, DOI: https://doi.org/10.3899/jrheum. 131547.
24.
Muangchan C, Canadian Scleroderma Research Group, Baron M, et al. The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review. J Rheumatol 2013; 40: 1545–1556, DOI: https://doi.org/10.3899/jrheum....
25.
Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265–1282, DOI: 10.1002/art. 1780370902.
26.
Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008; 53: 1163–1174, DOI: 10.1007/s10620-007-0018-8.
27.
Mayes MD, Lacey Jr JV, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246–2255, DOI: 10.1002/art.11073.
28.
Piao X, Ying GW, Chaney MJ. Chronic Idiopathic Intestinal Pseudo-Obstruction. Cureus 2021; 13: e16563, DOI: 10.7759/cureus.16563.
29.
Zenzeri L, Tambucci R, Quitadamo P, et al. Update on chronic intestinal pseudo-obstruction. Curr Opin Gastroenterol 2020; 36: 1, DOI: 10.1097/MOG.0000000000000630.
30.
Mareth K, Alsaad AA, Roy A. Pneumatosis intestinalis in small bowel obstruction. BMJ Case Rep 2018; 2018: bcr2018224684, DOI: 10.1136/bcr-2018-224684.
31.
Ho LM, Paulson EK, Thompson WM. Pneumatosis Intestinalis in the Adult: Benign to Life-Threatening Causes. AJR Am J Roentgenol 2007; 188: 1604–1613, DOI: 10.2214/AJR.06.1309.
32.
Seket B, Kaczmarek D, Tiffet O. Intestinal Pseudo-Obstruction and Pneumatosis Cystoides Intestinalis in a Scleroderma Patient. J Am Coll Surg 2007; 205: 180–181, DOI: 10.1016/ j.jamcollsurg.2006.08.025.
33.
Emmanuel AV, Shand AG, Kamm MA. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther 2004; 19: 687–694, DOI: 10.1111/j.1365-2036.2004. 01900.x.
34.
Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461–1467, DOI: 10.1056/NEJM199111213252102.
35.
Shindo K, Machida M, Koide K, et al. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology 1998; 45: 1643–1650.
36.
Numajiri H, Kuzumi A, Fukasawa T, et al. B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. Arthritis Rheumatol 2021; 73: 2086–2095, DOI: 10.1002/art.41798.
37.
Ebata S, Yoshizaki A, Fukasawa T, et al. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis- associated interstitial lung disease. J Dermatol 2019; 46: 1006–1013, DOI: 10.1111/1346-8138.15079.
38.
Rozman B, Cucnik S, Sodin-Semrl S, et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 2008; 67: 1282–1286, DOI: 10.1136/ard.2007.073981.
39.
Abbasi S, Parmar G, Kelly RD, et al. The Ku complex: recent advances and emerging roles outside of non-homologous end-joining. Cell Mol Life Sci 2021; 78: 4589–4613, DOI: 10.1007/s00018-021-03801-1.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
ARTYKUŁ POWIĄZANY
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
Przetwarzamy dane osobowe zbierane podczas odwiedzania serwisu. Realizacja funkcji pozyskiwania informacji o użytkownikach i ich zachowaniu odbywa się poprzez dobrowolnie wprowadzone w formularzach informacje oraz zapisywanie w urządzeniach końcowych plików cookies (tzw. ciasteczka). Dane, w tym pliki cookies, wykorzystywane są w celu realizacji usług, zapewnienia wygodnego korzystania ze strony oraz w celu monitorowania ruchu zgodnie z Polityką prywatności. Dane są także zbierane i przetwarzane przez narzędzie Google Analytics (więcej).
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
